The aim of the study was to investigate whether interleukin-10 (IL-10) genetic polymorphisms influence this cytokine production as well as the incidence and outcome of diffuse large B-cell lymphoma (DLBCL). The frequency of IL-10 -1082G allele was found to be higher in 199 patients with DLBCL as compared with 112 control subjects (0.47 versus 0.39, P ؍ .043). Increased serum levels of IL-10 were associated with adverse prognostic factors and poor DLBCL outcome. The frequencies of IL-10 -819T and IL-10 -592A alleles were lower in patients with elevated IL-10 serum levels (0.155 versus 0.32, P ؍ .14).
Tumor necrosis factor (TNF) production and non-Hodgkin lymphoma (NHL) outcome was found to be related to the TNF ؊308 polymorphism. To explore whether this could be linked to neighboring polymorphisms, we genotyped the TNF ؊376,؊308,؊238,؊163 , lymphotoxin alpha (LT␣) ؉252 , and HLA DRB1 alleles in 204 patients with NHL and 120 controls. TNF ؊308A was the only allele associated with higher TNF and its p55 and p75 receptors' levels (P ؍ .009, P ؍ .03, and P ؍ .007) and lower complete remission rates (P ؍ .006). Freedom from progression (FFP) and overall survival (OS) were shorter in patients with TNF ؊308A (P ؍ .009 and P ؍ .02), null HLA DRB1*02 allele (P ؍ .007 and P ؍ .14), or both genetic markers (P ؍ .004 and P ؍ .005
Compared to de novo DLBCL, transformed NHL at diagnosis have similar overall survival but lower complete response to initial treatment and higher risk of indolent relapses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.